Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort

Journal of Medical Virology

Volumn 83, Issue 2, 2011, Pages 187-195

  Reuter, Stefan ^a   Oette, Mark ^b   Sichtig, Nadine ^c   Kaiser, Rolf ^c   Balduin, Melanie ^c   Jensen, Björn ^a   Häussinger, Dieter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Krankenhaus der Augustinerinnen   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Mutational pattern; Na ve; Resistance; Selection pressure; Transmission

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; VIRUS MUTATION; WILD TYPE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650347570     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21971     Document Type: Article

References (46)

1. Allen TM, Altfeld M. 2003. HIV-1 superinfection. J Allergy Clin Immunol 112: 829-835.
2. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM. 2004. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18: 1683-1689.
3. Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, McLean K, Porter K. 2004. Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS 18: 1471-1473.
4. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76: 1753-1761.
5. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA. 2004. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18: 1653-1660.
6. Cane PA. 2005. Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis 18: 537-542.
7. Capetti AF, Gabris AI, Drago L, Vigevani GM. 2005. Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure? AIDS 19: 633-634.
8. Cane P, Dean G, Fisher M, Pao D, Drake S. Pillay D., 2009. Persistence of primary genotypic resistance following HIV-1 seroconversion for up to three years post infection. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Poster 684.
9. Chan KC, Galli RA, Montaner JS, Harrigan PR. 2003. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 17: 1256-1258.
10. Chang SY, Chen MY, Lee CN, Sun HY, Ko W, Chang SF, Chang KL, Hsieh SM, Sheng WH, Liu WC, Wu CH, Kao CL, Hung CC, Chang SC. 2008. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 61: 689-693.
11. Clumeck N, Pozniak A, Raffi F. 2008. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 9: 65-71.
12. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
13. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V. 2004. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 9: 415-421.
14. Dilernia DA, Lourtau L, Gomez AM, Ebenrstejin J, Toibaro JJ, Bautista CT, Marone R, Carobene M, Pampuro S, Gomez-Carrillo M, Losso MH, Salomon H. 2007. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 21: 1355-1360.
15. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kucherer C. 2001. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26: 266-273.
16. Fox J, Dustan S, McClure M, Weber J, Fidler S. 2006. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 7: 477-483.
17. German-Austrian guidelines. 2009. Antiretroviral therapy of HIV infection (position in September 2008). Dtsch Med Wochenschr 134: S4-S15.
18. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML. 2006. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20: 159-170.
19. Han X, Zhang M, Dai D, Wang Y, Zhang Z, Liu J, Geng W, Jiang Y, Takebe Y, Shang H. 2007. Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference. AIDS Res Hum Retroviruses 23: 357-364.
20. Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, Ngo N, Rouzioux C, Goujard C, Hoen B, Sereni D, Delfraissy JF, Meyer L. 2002. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 16: 793-796.
21. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47: 266-285.
22. Horban A, Stanczak JJ, Bakowska E, Tobolewska EJ, Przybylska-Stengiel KJ, Stanczak GP, Burkacka E. 2002. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort. Infection 30: 356-359.
23. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
24. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy JF. 2004. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18: 1147-1158.
25. Lazzari S, de FA, Sobel H, Bertagnolio S. 2004. HIV drug resistance surveillance: summary of an April 2003 WHO consultation. AIDS 18: S49-S53.
26. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD. 2008. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82: 5510-5518.
27. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
28. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Gunthard HF, Cavassini M. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 48: 239-247.
29. Mueller SM, Schaetz B, Eismann K, Bergmann S, Bauerle M, Schmitt-Haendle M, Walter H, Schmidt B, Korn K, Sticht H, Spriewald B, Harrer EG, Harrer T. 2007. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease. J Virol 81: 2887-2898.
30. Oette M, Kaiser R, Daumer M, Akbari D, Fatkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmaloer D, Gobels K, Vogt C, Wettstein M, Häussinger D. 2004. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 9: 273-278.
31. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, Carls H, Rockstroh JK, Schmaloer D, Stechel J, Feldt T, Pfister H, Häussinger D. 2006. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41: 573-581.
32. Palacios R, Viciana I, Perez dPedro I, de la Torre J, Ropero F, Fernandez S, Salgado F, Roldan J, de Dios Colmenero J, Marquez M, Santos J. 2008. Prevalence of primary resistance mutations in patients with newly diagnosed HIV infection in the province of Malaga (Spain). Enferm Infecc Microbiol Clin 26: 141-145.
33. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, Green T, Kumar S, Murphy M, Tang A, Taylor S, White D, Underhill G, Pillay D, Cane P. 2004. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 37: 1570-1573.
34. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, Dupke S, Jessen H, Hamouda O. 2007. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 8: 511-519.
35. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, Knechten H, Schmutz G, Hower M, Emmelkamp J, Pfister H, Haussinger D. 2007. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848.
36. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14: F17-F23.
37. Sanchez OM, Lopez MJ, Santana MA, Andes JM, Campelo FA. 2007. Primary antiretroviral drug resistance among patients diagnosed with HIV infection in Gran Canaria (Spain) between 2002 and 2005. Enferm Infecc Microbiol Clin 25: 437-440.
38. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 41: 439-446.
39. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
40. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M. 2002. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16: 1511-1519.
41. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
42. Tang JW, Pillay D. 2004. Transmission of HIV-1 drug resistance. J Clin Virol 30: 1-10.
43. Varella RB, Ferreira SB, de Castro MB, Zalis MG, Tavares MD. 2007. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro. Brazil J Med Virol 79: 1033-1039.
44. von Hentig N, Babacan E, Staszewski S, Sturmer M, Doerr HW, Lotsch J. 2007. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir Ther 12: 1237-1246.
45. Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait MH, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. 2004. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 48: 644-647.
46. Yerly S, von W V, Ledergerber B, Boni J, Schupbach J, Burgisser P, Klimkait T, Rickenbach M, Kaiser L, Gunthard HF, Perrin L. 2007. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-2229.